FDA Inspection
Continental Services Group, Inc.Continental Services Group, Inc. – FDA Inspection, May 31, 2019
Record Details
This FDA Inspection record concerns Continental Services Group, Inc., with an inspection on May 31, 2019, issued by the Center for Biologics Evaluation and Research, covering biologics.
View Company Profile
ID · d8e4a6b0-caa9-4ca8-a313-6264ef49c315
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1091317
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 606.100(b)Establish, maintain and follow manufacturing SOPs
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Continental Services Group, Inc.
7| Date | Classification | Office | Project area |
|---|---|---|---|
| April 30, 2026 | Not classified | Florida District Office | Blood and Blood Products |
| July 24, 2024 | VAI | Florida District Office | Blood and Blood Products |
| August 24, 2022 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| October 1, 2014 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| September 27, 2013 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for Continental Services Group, Inc.
- FDA Inspection 1314786 - 2026-04-30
- FDA Inspection 1244489 - 2024-07-24
- FDA Inspection 1178109 - 2022-08-24
- FDA Inspection 899467 - 2014-10-01
- FDA Inspection 850881 - 2013-09-27
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.